License, Collaboration and Other Significant Agreements - U.S. Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2016 USD ($)	Jul. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) performance_obligation	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Apr. 01, 2019	Mar. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue			$ 48,964	$ 48,756	$ 237,422	$ 153,973
Revenue recognized			5,047	9,159	29,574	20,363
Non cash revenue recognized					9,550	0
Deferred revenue			44,561		44,561
Prepaid expenses and other current assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable			5,609	3,442	5,609	3,442	$ 4,309	$ 1,722
Accounts payable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue			0	0	0	0	3,171	$ 7,227
License, collaboration and other revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue			6,725	12,003	110,032	53,853
Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. and International Agreement | License, collaboration and other revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue			0		$ 92,300
Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of performance obligations | performance_obligation					3
Percentage of costs funded by customer									80.00%	52.50%
Reimbursement of costs	$ 33,800
Collaborative arrangements cost sharing payments					$ 319,200
Cumulative catch-up adjustment to revenue, modification of contract		$ 55,000
Revenue recognized			15,500
Non cash revenue recognized			9,600
Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Prepaid expenses and other current assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable			5,600		5,600		3,000
Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Accounts payable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue							$ 2,000
Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | License, collaboration and other revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recognized revenue			$ 0	$ 6,144	86,773	$ 28,988
Otsuka Pharmaceutical Company. Ltd. | Otsuka U.S. Agreement | Up Front Non Refundable And Non Creditable
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront cash payment received					$ 125,000